ACR适宜性标准®:肾上腺癌的分期与随访
美国放射学会适宜性标准针对肾上腺皮质癌与嗜铬细胞瘤的分期、再分期和监测给出影像推荐。肾上腺皮质癌推荐腹部和盆腔增强MRI或CT、胸部增强CT及FDG-PET/CT或PET/MRI;嗜铬细胞瘤推荐上述MRI或CT、胸部增强CT及DOTATATE PET/CT或PET/MRI,MIBG扫描为可接受的替代方案。
要点
- 肾上腺皮质癌分期与随访推荐腹部和盆腔增强MRI或CT、胸部增强CT及FDG-PET/CT或PET/MRI。
- 嗜铬细胞瘤分期与随访推荐腹部和盆腔增强MRI或CT、胸部增强CT及DOTATATE PET/CT或PET/MRI。
- MIBG全身SPECT或SPECT/CT可作为嗜铬细胞瘤初始分期的可接受替代,尤其用于判断碘-131 MIBG治疗资格。
核心结论
- 对已知或疑似肾上腺皮质癌及嗜铬细胞瘤,推荐使用腹部和盆腔增强MRI或CT、胸部增强CT及相应功能成像进行初始分期、再分期或监测,以评估局部范围、远处转移或复发。
研究设计与样本
- 美国放射学会适宜性标准为循证指南,由多学科专家小组每年审查,采用GRADE等既定方法学原则评估证据,并依据RAND/UCLA适宜性方法用户手册确定影像与治疗程序的适宜性;文献缺乏或模棱两可时,专家可作为主要证据来源形成推荐。
诊断标准与关键数值
- 对已知或疑似肾上腺皮质癌,推荐腹部和盆腔平扫加增强MRI、腹部和盆腔增强CT、胸部增强CT、FDG-PET/CT或FDG-PET/MRI,以评估局部范围与远处转移或评估复发。
- 对已知或疑似嗜铬细胞瘤,推荐腹部和盆腔平扫加增强MRI、腹部和盆腔增强CT、胸部增强CT、DOTATATE PET/CT或DOTATATE PET/MRI,以评估局部范围与远处转移或评估复发。
- MIBG全身SPECT或感兴趣区SPECT/CT是已知或疑似嗜铬细胞瘤初始分期的可接受替代方案,尤其用于确定碘-131 MIBG治疗的资格。
临床应用与阅片要点
- 阅片和报告肾上腺皮质癌分期或随访时,按指南推荐覆盖腹部和盆腔增强MRI或CT、胸部增强CT及FDG-PET/CT或PET/MRI。
- 阅片和报告嗜铬细胞瘤分期或随访时,按指南推荐覆盖腹部和盆腔增强MRI或CT、胸部增强CT及DOTATATE PET/CT或PET/MRI。
- 当需要判断嗜铬细胞瘤患者是否适合碘-131 MIBG治疗时,可采用MIBG全身SPECT或SPECT/CT作为初始分期的可接受替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Primary adrenal gland malignancies include adrenocortical carcinoma (ACC) and pheochromocytoma. For initial staging and restaging or surveillance of known or suspected ACC, MRI of the abdomen and pelvis without and with contrast, CT of the abdomen and pelvis with contrast, CT of the chest with contrast, and fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT, or FDG-PET/MRI are recommended to assess for local extent and distant metastases or to evaluate for recurrence. For initial staging and restaging or surveillance of known or suspected pheochromocytoma, MRI of the abdomen and pelvis without and with contrast, CT of the abdomen and pelvis with contrast, CT of the chest with contrast, DOTATATE PET/CT, or DOTATATE PET/MRI are recommended to assess local extent and distant metastases or to evaluate for recurrence. Meta-iodobenzylguanidine (MIBG) scan whole body with single-photon emission CT (SPECT) or SPECT/CT area of interest is an acceptable alternative for initial staging of known or suspected pheochromocytoma, in particular to determine eligibility for I-131 MIBG therapy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
引用
- Chang SD, Jeavons C, Ulaner GA, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Adrenal Cancer. J Am Coll Radiol. 2026. PMID: 41863523. doi:10.1016/j.jacr.2026.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。